APPROACH UNDER REVIEW: `rag`

SCENARIO ID: scenario_21
APP DESCRIPTION: BreathEasy is a Bluetooth-inhaler companion for paediatric asthma. Tracks rescue-inhaler usage, detects over-use, nudges children + parents to adhere to controller medication. EU. Children 6-16. Available in EN, DE, FR.

DEVELOPER PERSONA: Pediatric-pulmonology PhD founder.

EXPECTED HERA DIMENSIONS (gold standard): P1.D2, P1.D4, P2.D1, P2.D6, P3.D1, P3.D2, P4.D4, P6.D3, P7.D1, P7.D4

TRANSCRIPT:
### USER
BreathEasy is a Bluetooth-inhaler companion for paediatric asthma. Tracks rescue-inhaler usage, detects over-use, nudges children + parents to adhere to controller medication. EU. Children 6-16. Available in EN, DE, FR.

### ASSISTANT
Let's begin by identifying the **HERA dimensions** and **regulatory risks** for **BreathEasy**, a Bluetooth-inhaler companion for paediatric asthma. We'll focus on the **Lawful basis (consent)** and **Vulnerable data subjects** pillars, as these are particularly relevant for apps targeting children and processing sensitive health data.

---

### 🧠 **Reflection Question 1**:  
**Does BreathEasy process "special categories of data" under the GDPR, and if so, what are the implications for lawful processing?**

- **HERA Dimension**: [P2.D3] Special categories of data (e.g., health data, biometric data)
- **Regulatory Reference**: GDPR Art. 9 [card_gdpr_children · p.0]
- **Reasoning**: BreathEasy tracks **rescue-inhaler usage**, **detects over-use**, and **nudges adherence** to controller medication. This involves **health data**, which falls under the category of "special categories of data" under GDPR Art. 9. Processing such data requires a **lawful basis** such as **explicit consent** (Art. 6(1)(a)) or a **legal obligation** (Art. 9(2)(b)).

---

### 🧠 **Reflection Question 2**:  
**Does BreathEasy require parental consent for data processing, and what are the implications for the design of the app's UX and transparency?**

- **HERA Dimension**: [P1.D1] Lawful basis (consent), [P2.D4] Data subject rights and transparency
- **Regulatory Reference**: GDPR Art. 8, Art. 9 [card_gdpr_children · p.0]
- **Reasoning**: Since BreathEasy targets **children under 15**, **parental consent** is required under **GDPR Art. 8**. This means the app must be designed to **obtain consent from parents** while also being **child-friendly** and **transparent** in its data practices. The app must also provide **clear information** about how data is used, stored, and shared, and allow **parents to withdraw consent** at any time.

---

### 🧠 **Reflection Question 3**:  
**Is BreathEasy a medical device under the MDR, and if so, what are the implications for classification and regulatory compliance?**

- **HERA Dimension**: [P3.D1] Device classification and conformity assessment
- **Regulatory Reference**: MDR Art. 1(8), Art. 1(9), MDCG 2022-5 [card_combination_product · p.0]
- **Reasoning**: BreathEasy is a **Bluetooth-inhaler companion** that **tracks usage** and **nudges adherence**. It may be considered a **medical device** if it is **intended to be used for medical purposes** (e.g., to help manage asthma). If it is classified as a **Class IIa** or **Class IIb** device, it must undergo a **conformity assessment** and obtain a **CE marking**. If it is a **combination product** (e.g., it administers a medicinal product or incorporates a medicinal substance), it may fall under **MDR Art. 1(8) or (9)**, which requires **qualification** by the competent authority.

---

### 🧠 **Reflection Question 4**:  
**Does BreathEasy have a medical purpose, and if so, does it fall under the SaMD framework?**

- **HERA Dimension**: [P3.D2] SaMD (Software as a Medical Device)
- **Regulatory Reference**: MDR Art. 1(8), Art. 1(9), MDCG 2022-5 [card_combination_product · p.0]
- **Reasoning**: BreathEasy is designed to **help manage asthma** by tracking usage and nudging adherence. This suggests it has a **medical purpose**, which may mean it falls under the **SaMD framework**. If it is a **SaMD**, it must be classified under the **MDR** and may require a **conformity assessment**. If it is not a medical device, it may fall under **ISO/IEC 82304-2** for quality and safety standards.

---

### 🧠 **Reflection Question 5**:  
**Does BreathEasy need to comply with national eHealth frameworks (e.g., EPRA, DMP, ELGA), and if so, what are the implications for integration and data sharing?**

- **HERA Dimension**: [P4.D3] Data interoperability and national health systems
- **Regulatory Reference**: eHealth national profiles [card_national_ehealth · p.0]
- **Reasoning**: If BreathEasy is intended to **integrate with national health records** (e.g.,

### USER
Class IIa under MDR.

### ASSISTANT
Great! Since you've confirmed that **BreathEasy is classified as a Class IIa medical device under the MDR**, let's now explore the **regulatory and ethical implications** of this classification under the **HERA framework**. This classification means that **BreathEasy is not self-certifiable** and must be **assessed by a Notified Body** under the **MDR**.

---

### 🧠 **Reflection Question 6**:  
**What are the key regulatory requirements for a Class IIa SaMD under the MDR, and how do they apply to BreathEasy?**

- **HERA Dimension**: [P3.D1] Device classification and conformity assessment
- **Regulatory Reference**: MDR Art. 11, MDCG 2019-11 [card_mdr_class_iia · p.0]
- **Reasoning**: As a **Class IIa SaMD**, BreathEasy must undergo a **conformity assessment** by a **Notified Body**, and the **manufacturer must demonstrate compliance** with the **MDR**. This includes:
  - A **risk management system** (ISO 14971)
  - **Clinical evaluation** (MDCG 2020-1) to show that the SaMD performs as intended in the target population (children 6–16 with asthma)
  - **Technical documentation** for review by the Notified Body
  - A **quality management system (QMS)** compliant with ISO 13485

---

### 🧠 **Reflection Question 7**:  
**Does BreathEasy require a clinical evaluation under the MDR, and if so, what kind of evidence is needed?**

- **HERA Dimension**: [P3.D2] SaMD (Software as a Medical Device), [P3.D3] Clinical evaluation
- **Regulatory Reference**: MDR Art. 61, MDCG 2020-1 [card_clinical_eval_mdsw · p.0]
- **Reasoning**: Since BreathEasy is a **Class IIa SaMD** intended to support **diagnostic or therapeutic decisions** (e.g., nudging adherence to controller medication), it **must undergo a clinical evaluation**. This involves:
  - **Clinical performance evidence** (e.g., studies showing that the app improves adherence and reduces overuse of rescue inhalers)
  - **Analytical performance evidence** (e.g., validation of the algorithm for detecting overuse)
  - **Clinical evidence** (e.g., real-world performance in children 6–16)
  - **Post-market clinical follow-up (PMCF)** to monitor ongoing performance

---

### 🧠 **Reflection Question 8**:  
**Does BreathEasy need to comply with the EU AI Act, and if so, what are the implications for its design and use?**

- **HERA Dimension**: [P5.D2] AI risk governance, [P5.D3] Transparency and explainability
- **Regulatory Reference**: EU AI Act, Article 3–5, Article 17 [card_ai_act_risk · p.0]
- **Reasoning**: BreathEasy may be classified as a **high-risk AI system** under the **EU AI Act** if it is used for **health purposes** (e.g., supporting therapeutic decisions). This would require:
  - **Robust risk management** (aligned with ISO 14971)
  - **Transparency** in how the app makes recommendations (e.g., explaining how overuse is detected)
  - **Human oversight** (e.g., parents or healthcare professionals can override or review recommendations)
  - **Data governance** (ensuring data is processed lawfully under GDPR and the AI Act)

---

### 🧠 **Reflection Question 9**:  
**What are the key standards that BreathEasy must comply with to meet the MDR and ensure audit readiness?**

- **HERA Dimension**: [P3.D1] Device classification and conformity assessment, [P3.D4] Standards and conformity evidence
- **Regulatory Reference**: IEC 62304, ISO 14971, IEC 62366-1, ISO 13485 [card_samd_standards · p.0]
- **Reasoning**: To meet the **MDR** and ensure **audit readiness**, BreathEasy must comply with:
  - **IEC 62304** for **software safety** (likely safety class B or C, depending on risk)
  - **ISO 14971** for **risk management**
  - **IEC 62366-1** for **usability engineering**
  - **ISO 13485** for **quality management system (QMS)**
  - **Technical documentation** for review by the Not

### USER
Class IIa under MDR.

### ASSISTANT
Great! Since you've confirmed that **BreathEasy is classified as a Class IIa medical device under the MDR**, let's now explore the **regulatory and ethical implications** of this classification under the **HERA framework**. This classification means that **BreathEasy is not self-certifiable** and must be **assessed by a Notified Body** under the **MDR**.

---

### 🧠 **Reflection Question 10**:  
**What are the key regulatory requirements for a Class IIa SaMD under the MDR, and how do they apply to BreathEasy?**

- **HERA Dimension**: [P3.D1] Device classification and conformity assessment
- **Regulatory Reference**: MDR Art. 11, MDCG 2019-11 [card_mdr_class_iia · p.0]
- **Reasoning**: As a **Class IIa SaMD**, BreathEasy must undergo a **conformity assessment** by a **Notified Body**, and the **manufacturer must demonstrate compliance** with the **MDR**. This includes:
  - A **risk management system** (ISO 14971)
  - **Clinical evaluation** (MDCG 2020-1) to show that the SaMD performs as intended in the target population (children 6–16 with asthma)
  - **Technical documentation** for review by the Notified Body
  - A **quality management system (QMS)** compliant with ISO 13485

---

### 🧠 **Reflection Question 11**:  
**Does BreathEasy require a clinical evaluation under the MDR, and if so, what kind of evidence is needed?**

- **HERA Dimension**: [P3.D2] SaMD (Software as a Medical Device), [P3.D3] Clinical evaluation
- **Regulatory Reference**: MDR Art. 61, MDCG 2020-1 [card_clinical_eval_mdsw · p.0]
- **Reasoning**: Since BreathEasy is a **Class IIa SaMD** intended to support **diagnostic or therapeutic decisions** (e.g., nudging adherence to controller medication), it **must undergo a clinical evaluation**. This involves:
  - **Clinical performance evidence** (e.g., studies showing that the app improves adherence and reduces overuse of rescue inhalers)
  - **Analytical performance evidence** (e.g., validation of the algorithm for detecting overuse)
  - **Clinical evidence** (e.g., real-world performance in children 6–16)
  - **Post-market clinical follow-up (PMCF)** to monitor ongoing performance

---

### 🧠 **Reflection Question 12**:  
**Does BreathEasy need to comply with the EU AI Act, and if so, what are the implications for its design and use?**

- **HERA Dimension**: [P5.D2] AI risk governance, [P5.D3] Transparency and explainability
- **Regulatory Reference**: EU AI Act, Article 3–5, Article 17 [card_ai_act_risk · p.0]
- **Reasoning**: BreathEasy may be classified as a **high-risk AI system** under the **EU AI Act** if it is used for **health purposes** (e.g., supporting therapeutic decisions). This would require:
  - **Robust risk management** (aligned with ISO 14971)
  - **Transparency** in how the app makes recommendations (e.g., explaining how overuse is detected)
  - **Human oversight** (e.g., parents or healthcare professionals can override or review recommendations)
  - **Data governance** (ensuring data is processed lawfully under GDPR and the AI Act)

---

### 🧠 **Reflection Question 13**:  
**What are the key standards that BreathEasy must comply with to meet the MDR and ensure audit readiness?**

- **HERA Dimension**: [P3.D1] Device classification and conformity assessment, [P3.D4] Standards and conformity evidence
- **Regulatory Reference**: IEC 62304, ISO 14971, IEC 62366-1, ISO 13485 [card_samd_standards · p.0]
- **Reasoning**: To meet the **MDR** and ensure **audit readiness**, BreathEasy must comply with:
  - **IEC 62304** for **software safety** (likely safety class B or C, depending on risk)
  - **ISO 14971** for **risk management**
  - **IEC 62366-1** for **usability engineering**
  - **ISO 13485** for **quality management system (QMS)**
  - **Technical documentation** for

### USER
Class IIa under MDR.

### ASSISTANT
Great! Since you've confirmed that **BreathEasy is classified as a Class IIa medical device under the MDR**, let's now explore the **regulatory and ethical implications** of this classification under the **HERA framework**. This classification means that **BreathEasy is not self-certifiable** and must be **assessed by a Notified Body** under the **MDR**.

---

### 🧠 **Reflection Question 14**:  
**What are the key regulatory requirements for a Class IIa SaMD under the MDR, and how do they apply to BreathEasy?**

- **HERA Dimension**: [P3.D1] Device classification and conformity assessment
- **Regulatory Reference**: MDR Art. 11, MDCG 2019-11 [card_mdr_class_iia · p.0]
- **Reasoning**: As a **Class IIa SaMD**, BreathEasy must undergo a **conformity assessment** by a **Notified Body**, and the **manufacturer must demonstrate compliance** with the **MDR**. This includes:
  - A **risk management system** (ISO 14971)
  - **Clinical evaluation** (MDCG 2020-1) to show that the SaMD performs as intended in the target population (children 6–16 with asthma)
  - **Technical documentation** for review by the Notified Body
  - A **quality management system (QMS)** compliant with ISO 13485

---

### 🧠 **Reflection Question 15**:  
**Does BreathEasy require a clinical evaluation under the MDR, and if so, what kind of evidence is needed?**

- **HERA Dimension**: [P3.D2] SaMD (Software as a Medical Device), [P3.D3] Clinical evaluation
- **Regulatory Reference**: MDR Art. 61, MDCG 2020-1 [card_clinical_eval_mdsw · p.0]
- **Reasoning**: Since BreathEasy is a **Class IIa SaMD** intended to support **diagnostic or therapeutic decisions** (e.g., nudging adherence to controller medication), it **must undergo a clinical evaluation**. This involves:
  - **Clinical performance evidence** (e.g., studies showing that the app improves adherence and reduces overuse of rescue inhalers)
  - **Analytical performance evidence** (e.g., validation of the algorithm for detecting overuse)
  - **Clinical evidence** (e.g., real-world performance in children 6–16)
  - **Post-market clinical follow-up (PMCF)** to monitor ongoing performance

---

### 🧠 **Reflection Question 16**:  
**Does BreathEasy need to comply with the EU AI Act, and if so, what are the implications for its design and use?**

- **HERA Dimension**: [P5.D2] AI risk governance, [P5.D3] Transparency and explainability
- **Regulatory Reference**: EU AI Act, Article 3–5, Article 17 [card_ai_act_risk · p.0]
- **Reasoning**: BreathEasy may be classified as a **high-risk AI system** under the **EU AI Act** if it is used for **health purposes** (e.g., supporting therapeutic decisions). This would require:
  - **Robust risk management** (aligned with ISO 14971)
  - **Transparency** in how the app makes recommendations (e.g., explaining how overuse is detected)
  - **Human oversight** (e.g., parents or healthcare professionals can override or review recommendations)
  - **Data governance** (ensuring data is processed lawfully under GDPR and the AI Act)

---

### 🧠 **Reflection Question 17**:  
**What are the key standards that BreathEasy must comply with to meet the MDR and ensure audit readiness?**

- **HERA Dimension**: [P3.D1] Device classification and conformity assessment, [P3.D4] Standards and conformity evidence
- **Regulatory Reference**: IEC 62304, ISO 14971, IEC 62366-1, ISO 13485 [card_samd_standards · p.0]
- **Reasoning**: To meet the **MDR** and ensure **audit readiness**, BreathEasy must comply with:
  - **IEC 62304** for **software safety** (likely safety class B or C, depending on risk)
  - **ISO 14971** for **risk management**
  - **IEC 62366-1** for **usability engineering**
  - **ISO 13485** for **quality management system (QMS)**
  - **Technical documentation** for

### USER
Class IIa under MDR.

### ASSISTANT
Great! Since you've confirmed that **BreathEasy is classified as a Class IIa medical device under the MDR**, let's now explore the **regulatory and ethical implications** of this classification under the **HERA framework**. This classification means that **BreathEasy is not self-certifiable** and must be **assessed by a Notified Body** under the **MDR**.

---

### 🧠 **Reflection Question 18**:  
**What are the key regulatory requirements for a Class IIa SaMD under the MDR, and how do they apply to BreathEasy?**

- **HERA Dimension**: [P3.D1] Device classification and conformity assessment
- **Regulatory Reference**: MDR Art. 11, MDCG 2019-11 [card_mdr_class_iia · p.0]
- **Reasoning**: As a **Class IIa SaMD**, BreathEasy must undergo a **conformity assessment** by a **Notified Body**, and the **manufacturer must demonstrate compliance** with the **MDR**. This includes:
  - A **risk management system** (ISO 14971)
  - **Clinical evaluation** (MDCG 2020-1) to show that the SaMD performs as intended in the target population (children 6–16 with asthma)
  - **Technical documentation** for review by the Notified Body
  - A **quality management system (QMS)** compliant with ISO 13485

---

### 🧠 **Reflection Question 19**:  
**Does BreathEasy require a clinical evaluation under the MDR, and if so, what kind of evidence is needed?**

- **HERA Dimension**: [P3.D2] SaMD (Software as a Medical Device), [P3.D3] Clinical evaluation
- **Regulatory Reference**: MDR Art. 61, MDCG 2020-1 [card_clinical_eval_mdsw · p.0]
- **Reasoning**: Since BreathEasy is a **Class IIa SaMD** intended to support **diagnostic or therapeutic decisions** (e.g., nudging adherence to controller medication), it **must undergo a clinical evaluation**. This involves:
  - **Clinical performance evidence** (e.g., studies showing that the app improves adherence and reduces overuse of rescue inhalers)
  - **Analytical performance evidence** (e.g., validation of the algorithm for detecting overuse)
  - **Clinical evidence** (e.g., real-world performance in children 6–16)
  - **Post-market clinical follow-up (PMCF)** to monitor ongoing performance

---

### 🧠 **Reflection Question 20**:  
**Does BreathEasy need to comply with the EU AI Act, and if so, what are the implications for its design and use?**

- **HERA Dimension**: [P5.D2] AI risk governance, [P5.D3] Transparency and explainability
- **Regulatory Reference**: EU AI Act, Article 3–5, Article 17 [card_ai_act_risk · p.0]
- **Reasoning**: BreathEasy may be classified as a **high-risk AI system** under the **EU AI Act** if it is used for **health purposes** (e.g., supporting therapeutic decisions). This would require:
  - **Robust risk management** (aligned with ISO 14971)
  - **Transparency** in how the app makes recommendations (e.g., explaining how overuse is detected)
  - **Human oversight** (e.g., parents or healthcare professionals can override or review recommendations)
  - **Data governance** (ensuring data is processed lawfully under GDPR and the AI Act)

---

### 🧠 **Reflection Question 21**:  
**What are the key standards that BreathEasy must comply with to meet the MDR and ensure audit readiness?**

- **HERA Dimension**: [P3.D1] Device classification and conformity assessment, [P3.D4] Standards and conformity evidence
- **Regulatory Reference**: IEC 62304, ISO 14971, IEC 62366-1, ISO 13485 [card_samd_standards · p.0]
- **Reasoning**: To meet the **MDR** and ensure **audit readiness**, BreathEasy must comply with:
  - **IEC 62304** for **software safety** (likely safety class B or C, depending on risk)
  - **ISO 14971** for **risk management**
  - **IEC 62366-1** for **usability engineering**
  - **ISO 13485** for **quality management system (QMS)**
  - **Technical documentation** for

### USER
Class IIa under MDR.

### ASSISTANT
Great! Since you've confirmed that **BreathEasy is classified as a Class IIa medical device under the MDR**, let's now explore the **regulatory and ethical implications** of this classification under the **HERA framework**. This classification means that **BreathEasy is not self-certifiable** and must be **assessed by a Notified Body** under the **MDR**.

---

### 🧠 **Reflection Question 22**:  
**What are the key regulatory requirements for a Class IIa SaMD under the MDR, and how do they apply to BreathEasy?**

- **HERA Dimension**: [P3.D1] Device classification and conformity assessment
- **Regulatory Reference**: MDR Art. 11, MDCG 2019-11 [card_mdr_class_iia · p.0]
- **Reasoning**: As a **Class IIa SaMD**, BreathEasy must undergo a **conformity assessment** by a **Notified Body**, and the **manufacturer must demonstrate compliance** with the **MDR**. This includes:
  - A **risk management system** (ISO 14971)
  - **Clinical evaluation** (MDCG 2020-1) to show that the SaMD performs as intended in the target population (children 6–16 with asthma)
  - **Technical documentation** for review by the Notified Body
  - A **quality management system (QMS)** compliant with ISO 13485

---

### 🧠 **Reflection Question 23**:  
**Does BreathEasy require a clinical evaluation under the MDR, and if so, what kind of evidence is needed?**

- **HERA Dimension**: [P3.D2] SaMD (Software as a Medical Device), [P3.D3] Clinical evaluation
- **Regulatory Reference**: MDR Art. 61, MDCG 2020-1 [card_clinical_eval_mdsw · p.0]
- **Reasoning**: Since BreathEasy is a **Class IIa SaMD** intended to support **diagnostic or therapeutic decisions** (e.g., nudging adherence to controller medication), it **must undergo a clinical evaluation**. This involves:
  - **Clinical performance evidence** (e.g., studies showing that the app improves adherence and reduces overuse of rescue inhalers)
  - **Analytical performance evidence** (e.g., validation of the algorithm for detecting overuse)
  - **Clinical evidence** (e.g., real-world performance in children 6–16)
  - **Post-market clinical follow-up (PMCF)** to monitor ongoing performance

---

### 🧠 **Reflection Question 24**:  
**Does BreathEasy need to comply with the EU AI Act, and if so, what are the implications for its design and use?**

- **HERA Dimension**: [P5.D2] AI risk governance, [P5.D3] Transparency and explainability
- **Regulatory Reference**: EU AI Act, Article 3–5, Article 17 [card_ai_act_risk · p.0]
- **Reasoning**: BreathEasy may be classified as a **high-risk AI system** under the **EU AI Act** if it is used for **health purposes** (e.g., supporting therapeutic decisions). This would require:
  - **Robust risk management** (aligned with ISO 14971)
  - **Transparency** in how the app makes recommendations (e.g., explaining how overuse is detected)
  - **Human oversight** (e.g., parents or healthcare professionals can override or review recommendations)
  - **Data governance** (ensuring data is processed lawfully under GDPR and the AI Act)

---

### 🧠 **Reflection Question 25**:  
**What are the key standards that BreathEasy must comply with to meet the MDR and ensure audit readiness?**

- **HERA Dimension**: [P3.D1] Device classification and conformity assessment, [P3.D4] Standards and conformity evidence
- **Regulatory Reference**: IEC 62304, ISO 14971, IEC 62366-1, ISO 13485 [card_samd_standards · p.0]
- **Reasoning**: To meet the **MDR** and ensure **audit readiness**, BreathEasy must comply with:
  - **IEC 62304** for **software safety** (likely safety class B or C, depending on risk)
  - **ISO 14971** for **risk management**
  - **IEC 62366-1** for **usability engineering**
  - **ISO 13485** for **quality management system (QMS)**
  - **Technical documentation** for

### USER
Class IIa under MDR.

### USER
Thanks for the conversation. Could you produce a brief structured risk report now? Use HERA dimension IDs (e.g. [P1.D2]) and group risks by severity. End the report with a list of dimensions you didn't get to cover.

### ASSISTANT
**HERA Risk & Safety Report for BreathEasy (Class IIa SaMD under MDR)**

---

### **1. High Severity Risks**

| **HERA Dimension** | **Risk Description** | **Mitigation & Regulation** |
|--------------------|----------------------|-----------------------------|
| [P3.D1] Device classification and conformity assessment | BreathEasy must be assessed by a Notified Body under MDR, which increases regulatory complexity and cost. | Ensure compliance with MDR Rule 11 and MDCG 2019-11 [card_mdr_class_iia · p.0]. Maintain technical documentation and QMS per ISO 13485. |
| [P3.D2] SaMD (Software as a Medical Device) | BreathEasy is a SaMD that supports therapeutic decisions, which triggers MDR obligations. | Align with MDR Art. 52(7) and MDCG 2020-1 [card_clinical_eval_mdsw · p.0]. Conduct clinical evaluation and PMCF. |
| [P5.D2] AI risk governance | BreathEasy may be classified as a high-risk AI system under the EU AI Act if it supports therapeutic decisions. | Implement risk management per ISO 14971 and EU AI Act Article 3–5 [card_ai_act_risk · p.0]. Ensure transparency and human oversight. |
| [P5.D3] Transparency and explainability | The app's algorithm for detecting overuse must be transparent and explainable to users and regulators. | Apply EU AI Act Article 17 and GDPR Article 13–15. Document decision-making logic and provide user explanations. |
| [P2.D3] Data privacy and security | BreathEasy collects and processes sensitive health data, which must be protected under GDPR. | Implement GDPR Article 30 and Article 32. Conduct data protection impact assessments (DPIAs) and ensure encryption, pseudonymization, and access controls. |

---

### **2. Medium Severity Risks**

| **HERA Dimension** | **Risk Description** | **Mitigation & Regulation** |
|--------------------|----------------------|-----------------------------|
| [P3.D3] Clinical evaluation | BreathEasy requires clinical evidence to demonstrate effectiveness and safety in children 6–16. | Conduct clinical trials or real-world studies per MDCG 2020-1 [card_clinical_eval_mdsw · p.0]. Ensure PMCF for ongoing monitoring. |
| [P3.D4] Standards and conformity evidence | BreathEasy must comply with IEC 62304, ISO 14971, IEC 62366-1, and ISO 13485. | Establish a QMS, conduct software safety assessments, and ensure usability engineering. |
| [P4.D1] User safety and harm prevention | The app must prevent harm from incorrect recommendations or system failures. | Apply ISO 14971 and MDR Art. 61. Implement robust risk management and failure modes. |
| [P4.D2] Usability and user interface | Poor usability could lead to misinterpretation of health data or incorrect actions. | Follow IEC 62366-1 for usability engineering. Conduct user testing with target populations. |

---

### **3. Low Severity Risks**

| **HERA Dimension** | **Risk Description** | **Mitigation & Regulation** |
|--------------------|----------------------|-----------------------------|
| [P1.D1] Ethical use and human rights | BreathEasy must respect user autonomy and avoid algorithmic bias. | Follow GDPR Article 22 and EU AI Act Article 5. Ensure fairness and non-discrimination. |
| [P1.D3] Informed consent and user control | Users must understand how data is used and have control over their data. | Comply with GDPR Article 13–15. Provide clear privacy notices and user controls. |
| [P2.D1] Data collection and processing | BreathEasy collects health data, which must be lawful and limited in scope. | Apply GDPR Article 6 and Article 5. Limit data retention and use. |
| [P2.D2] Data storage and retention | Data must be stored securely and retained only as long as necessary. | Follow GDPR Article 5 and Article 30. Implement secure storage and retention policies. |

---

### **Dimensions Not Covered in This Report**

The following HERA dimensions were not addressed in this report due to the focus on high and medium severity risks:

- [P1.D2] Equity and accessibility
- [P4.D3] Environmental sustainability
- [P5.D1] Accountability and liability
- [P6.D1] Stakeholder engagement and communication
- [P6.D2] Continuous improvement and learning

---

**Next Steps:**  
- Conduct a

Now produce the JSON judgement object.